91 related articles for article (PubMed ID: 17627418)
1. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.
Buckley SE; Saran FH; Gaze MN; Chittenden S; Partridge M; Lancaster D; Pearson A; Flux GD
Cancer Biother Radiopharm; 2007 Feb; 22(1):105-12. PubMed ID: 17627418
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
3. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
5. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.
Buckley SE; Chittenden SJ; Saran FH; Meller ST; Flux GD
J Nucl Med; 2009 Sep; 50(9):1518-24. PubMed ID: 19713562
[TBL] [Abstract][Full Text] [Related]
6. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
7. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
8. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.
Seo Y; Gustafson WC; Dannoon SF; Nekritz EA; Lee CL; Murphy ST; VanBrocklin HF; Hernandez-Pampaloni M; Haas-Kogan DA; Weiss WA; Matthay KK
Mol Imaging Biol; 2012 Dec; 14(6):735-42. PubMed ID: 22382618
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the dicentric chromosome assay as a biodosimetry tool for more personalized medicine in a case of a high risk neuroblastoma
Chimeno JM; Sebastià N; Torres-Espallardo I; Balaguer J; Candela-Juan C; Loaiza JL; Adria M; Ibanez-Rosello B; Cañete A; Martí-Bonmatí L; Montoro A
Int J Radiat Biol; 2019 Mar; 95(3):314-320. PubMed ID: 30496023
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma.
Sudbrock F; Schmidt M; Simon T; Eschner W; Berthold F; Schicha H
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1279-90. PubMed ID: 20179922
[TBL] [Abstract][Full Text] [Related]
11. Reaching the target dose with one single
Fiz F; Cirone A; Righi S; Massollo M; Amoroso L; Bottoni G; Conte M; Gambaro M; Massone F; Orengo S; Bruzzone GS; Sorrentino S; Garaventa A; Piccardo A
Pediatr Blood Cancer; 2024 Mar; 71(3):e30806. PubMed ID: 38082548
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Organ Dosimetry for Planning Repeat Treatments of High-Dose 131I-MIBG Therapy: 123I-MIBG Versus Posttherapy 131I-MIBG Imaging.
Pandit-Taskar N; Zanzonico P; Hilden P; Ostrovnaya I; Carrasquillo JA; Modak S
Clin Nucl Med; 2017 Oct; 42(10):741-748. PubMed ID: 28759518
[TBL] [Abstract][Full Text] [Related]
13. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
14. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
[TBL] [Abstract][Full Text] [Related]
15. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
16. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG.
Flux GD; Guy MJ; Papavasileiou P; South C; Chittenden SJ; Flower MA; Meller ST
Cancer Biother Radiopharm; 2003 Feb; 18(1):81-7. PubMed ID: 12667311
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.
Roa WH; Yaremko B; McEwan A; Amanie J; Yee D; Cho J; McQuarrie S; Riauka T; Sloboda R; Wiebe L; Loebenberg R; Janicki C
Technol Cancer Res Treat; 2013 Feb; 12(1):79-90. PubMed ID: 22974332
[TBL] [Abstract][Full Text] [Related]
18. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
19. [Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG].
Sudbrock F; Eschner W; Schmidt M; Simon T; Hero B; Schicha H
Nuklearmedizin; 2006; 45(6):254-61. PubMed ID: 17149494
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE; Wheldon TE; Gaze MN; Barrett A
Br J Radiol; 1995 May; 68(809):481-90. PubMed ID: 7788233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
